Exelixis

Originally published March 25.
The European Commission has approved Cometriq (cabozantinib) as a treatment for medullary thyroid cancer (MTC) patients.

Originally published Dec. 23.
EU's CHMP Issues Positive Opinion Exelixis' Cometriq for Medullary Thyroid Cancer

A team led by investigators at Cedars-Sinai Medical Center and the University of California, Los Angeles has developed a new approach for analyzing circulating tumor cells obtained from prostate cancer patients using chip- and sequencing-based applications.

European Commission Approves Vertex's Personalized CF Drug Kalydeco

Around the Regions

Premium

Gaithersburg West Master Plan, Ben Franklin Technology Partners, University of Houston Institute of Biomedical Research, Connecticut Economic Development Consolidations, South San Francisco Life Sciences Career Fair, New York City Biotechnology Tax Credit

Mice in New York harbor both antibiotic-resistant bacteria and novel viruses, according to a new analysis of their fecal microbiomes.

Human Heredity and Health in Africa Initiative has issued guidelines for genomic research in the region, according to Nature News.

The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.

In Genome Biology this week: approach to analyze alternative polyadenylation, algorithm to predict transcriptomic structural variations, and more.